ESR1 and breast cancer: Compared to well-established biomarkers in HR+/HER2− breast cancer, such as ESR1 mutations and PI3K/AKT pathway genes, CEACAM6 may offer complementary predictive value by capturing both chemotherapy sensitivity and immune microenvironment status.